Harvard Bioscience raised its full-year 2026 revenue growth guidance to 3% to 5%, up from a prior range of 2% to 4%, while adjusting its adjusted gross margin target to 57% to 59% from 58% to 60% due to product and geographic mix shifts. Second-quarter revenue came in at $22.7 million, an 11% year-over-year increase that exceeded the company's guidance range, driven by double-digit growth in its CMT and preclinical portfolios. Adjusted gross margin for the quarter was 57%, slightly below expectations because of higher-than-expected sales of lower-margin CMT products and sales in China. The company reaffirmed its full-year adjusted EBITDA growth guidance of 6% to 10% and reiterated that its Project Viking restructuring is expected to deliver $3 million in cost savings in 2027 and $4 million annually thereafter. For the third quarter, Harvard Bioscience expects revenue between $21 million and $22.6 million, with adjusted gross margin of 56% to 58% and adjusted EBITDA of $1.5 million to $2.5 million.
Harvard Bioscience IncRaises full-year revenue growth guidance and beats Q2 revenue expectations.
